Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 3/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067808 | 0.89 | HDAC8 (0.41) | HDAC8 | |
| SCHEMBL4403267 | 0.87 | MDM2 (0.44) | KMOMDM2HDAC8 | |
| SCHEMBL14843883 | 0.85 | KMO (0.40) | KMO | |
| SCHEMBL4420284 | 0.83 | GRN (0.40) | SLC7A5PKMKMO | |
| SCHEMBL5067796 | 0.80 | CA1 (0.38) | PKMKMO | |
| SCHEMBL2333132 | 0.80 | KMT2A (0.57) | HDAC8 | |
| SCHEMBL6897797 | 0.78 | NPC1 (0.38) | PKMKMO | |
| SCHEMBL3136979 | 0.78 | SLC7A5 (0.68) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL4895993 | 0.78 | SLC7A5 (0.68) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3657476 | 0.77 | SLC7A5 (0.53) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3209334-A2 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Igenica Biotherapeutics, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8512707-B2 | Methods of treating drug-resistant cancers | SEATTLE GENETICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | SEATTLE GENETICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7750116-B1 | Antibody drug conjugate metabolites | SEATTLE GENETICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010004535-A2 | THERAPEUTIC METHODS AND COMPOSITIONS EMPLOYING PEPTIDE COMPOUNDS | NYBERG FRED (SE) | 2010-01-14 | — | — | WO | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | CD44, TP53, MKI67 | SLC7A5 4368/4885ALPI 782/4885PKM 2145/4885 |
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYTH3, CD47, FCGRT | SLC7A5 817/4885ALPI 1824/4885PKM 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.